313479-64-0Relevant academic research and scientific papers
Monocarboxylate transporter 1 inhibitors as potential anticancer agents
Gurrapu, Shirisha,Jonnalagadda, Sravan K.,Alam, Mohammad A.,Nelson, Grady L.,Sneve, Mary G.,Drewes, Lester R.,Mereddy, Venkatram R.
, p. 558 - 561 (2015/05/27)
Potent monocarboxylate transporter 1 inhibitors (MCT1) have been developed based on α-cyano-4-hydroxycinnamic acid template. Structure-activity relationship studies demonstrate that the introduction of p-N, N-dialkyl/diaryl, and o-methoxy groups into cyanocinnamic acid has maximal MCT1 inhibitory activity. Systemic toxicity studies in healthy ICR mice with few potent MCT1 inhibitors indicate normal body weight gains in treated animals. In vivo tumor growth inhibition studies in colorectal adenocarcinoma (WiDr cell line) in nude mice xenograft models establish that compound 27 exhibits single agent activity in inhibiting the tumor growth.
Alkyl substituent effects on J- or H-aggregate formation of bisazomethine dyes
Kinashi, Kenji,Lee, Kyun-Phyo,Matsumoto, Shinya,Ishida, Kenji,Ueda, Yasukiyo
, p. 783 - 788 (2012/02/05)
Bisazomethine dyes with terminal alkyl substituents of different chain lengths (BAR: R = 1, 2, 3, 4, 5 and 6) were synthesized and deposited on a glass substrate to investigate the effect of the alkyl chain length on aggregate formation. Methyl- and ethyl-substituted bisazomethine dyes (BA1 and BA2) formed J-aggregates in thin films (ca. 50 nm), whereas, propyl-, butyl-, pentyl- and hexyl-substituted derivatives (BA3, BA4, BA5 and BA6) formed H-aggregates in thin films (ca. 50 nm). The aggregate formation of the BARs changed drastically between ethyl- and propyl-substituents (BA2/BA3). However, no remarkable changes were observed in the surface morphologies of BA2 and BA3 films. It is suggested that the critical determinant of aggregate formation of BAR is the molecular packing in the film, which depends on the chain length of the terminal alkyl substituent.
Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis
-
, (2008/06/13)
Disclosed are compounds of the Formula I and their use in a method of inhibiting the aggregation of amyloid proteins and in a method of imaging amyloid deposits.
